Fig. 7From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s diseaseHippocampal atrophy over 96 weeks, displayed as correlation with the immunoglobulin G (IgG) titre AUC. Results are shown for completers (a, b) (n = 18) and for patients with a positive biomarker profile (c, d) (n = 9). Results are also shown with raw AUC values (a, c) and with AUC values corrected for disease severity (b, d). One patient with frontotemporal dementia and one patient with poor magnetic resonance imaging scan quality were excluded. HCV Hippocampal volumeBack to article page